Across sun-soaked Australian practices, a curious healthcare habit persists: thousands of patients leave general practice consultations each week with pathology forms marked for a 25-hydroxyvitamin D blood test.  However, many patients and the doctors ordering the tests may be unaware that unless a patient meets strict high-risk clinical criteria, Medicare will not foot the bill. 

Under Australian Medicare Benefits Schedule (MBS) regulations, a 25-hydroxyvitamin D serum test ($30.05 fee) is only subsidized when ordered for specific high-risk indications.  According to Medicare and guidelines from the Royal Australian College of General Practitioners (RACGP), a rebatable test is restricted to patients presenting with-

• Established Bone & Metabolic Conditions: Signs or symptoms of osteoporosis, osteomalacia, or rickets (in patients under 16). 
• Abnormal Lab Results: Raised alkaline phosphatase with otherwise normal liver function, hyperparathyroidism, hypocalcaemia, hypercalcaemia, or hypophosphataemia. 
• Malabsorption Disorders: Untreated coeliac disease, short bowel syndrome, inflammatory bowel disease, cystic fibrosis,
• or a history of bariatric surgery.
• Deeply pigmented skin, or severe and chronic lack of sun exposure due to residential, occupational, cultural & Medical reasons. 
• Renal Failure & Specific Medications: Chronic renal failure, renal transplant.

Long-term use of medications known to lower vitamin D (e.g., anticonvulsants). 
Exclusively breastfed infants with an additional risk factor, infants of mothers with known severe deficiency, or siblings under 16 of affected individuals. 

The RACGP Warning however says that "You will not receive a rebate from Medicare for a vitamin D test, unless you meet certain criteria."If an ordered test falls outside these parameters, the cost must be covered out-of-pocket by the patient or absorbed by the ordering facility. 

Despite explicit "Choosing Wisely" guidance from the RACGP advising doctors not to routinely test general populations, pregnant women, or healthy children, non-targeted testing remains widespread. 

Medical experts highlight several structural drivers behind these persistent ordering habits-

• Patient Demand & Consultation Pressure
• Patients frequently request screening for low energy, muscle aches, or general tiredness.

For a busy GP, explaining complex rebate rules during a short consultation can be challenging, making it simpler to fulfill the request.  Bundled Electronic "Order Sets": Practice software systems frequently feature pre-packaged blood panel templates (such as "Annual Checkup" or "Chronic Fatigue") that automatically include vitamin D.

Clinicians often order these bundles without manually unchecking the test. Doctors may practice defensively to ensure they do not miss an easily treatable contributor to vague symptoms, even though guidelines state that empiric treatment or lifestyle advice is cheaper and safer than screening.

When non-indicated tests are ordered, the outcomes are uneven across the health sector, Commercial Pathology Providers, Pathology labs receive service and processing fees whenever a test is performed, regardless of whether it meets MBS rebate criteria.

Patients face surprise out-of-pocket costs or unnecessary medicalization being labeled with "mild insufficiency" for levels that are naturally lower during winter months.  The Healthcare System: Routine over-screening drains healthcare resources and adds administrative burdens without improving overall health outcomes.  The RACGP advises GPs to manage low-risk patient requests by exploring underlying lifestyle concerns, emphasizing bone health through safe sun exposure (10–15 minutes several times weekly), weight-bearing exercise, and balanced diet rather than reaching for the pathology pad.